Picture of Avalo Therapeutics logo

AVTX — Avalo Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Avalo Therapeutics Inc expected to post a loss of $6.70 a share - Earnings Preview

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 5
(estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Avalo Therapeutics Inc
is for
a loss of $6.70 per share. 
    * The one available analyst rating on the shares is
"hold".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $35.00​, above​ its last closing price
of $11.05. ​​​

This summary was machine generated August 2 at 17:48 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Avalo Therapeutics

See all news